Saturday, 17 October 2026European Markets

METABOLIC EXPLORER Stock Went Up By Over 21% In The Last 5 Sessions

Loading stream...

(vianews) - shares of metabolic explorer (cac 40: metex.pa) jumped by a staggering 21.11% in 5 sessions from €0.9 to €1.09 at 14:08 est on friday, after two consecutive sessions in a row of gains. cac 40 is jumping 0.7% to €7,433.49, following the last session's upward trend.

metabolic explorer's last close was €1.07, 78.81% under its 52-week high of €5.05.

about metabolic explorer

metabolic explorer s.a., a biological chemistry company, engages in the development and industrialization of industrial fermentation processes as alternatives to petrochemical processes worldwide. the company also offers propanediol, butyric acid, butyric acid, glycolic acid, amino acid, and l-valine. its products are used in the formulation of cosmetics, textiles, polymer, animal nutrition, and health products or as intermediates for the synthesis of biomaterials. the company was incorporated in 1999 and is based in saint-beauzire, france.

earnings per share

as for profitability, metabolic explorer has a trailing twelve months eps of €-0.84.

yearly top and bottom value

metabolic explorer's stock is valued at €1.09 at 14:08 est, way below its 52-week high of €5.05 and way higher than its 52-week low of €0.90.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, metabolic explorer's stock is considered to be oversold (<=20).

more news about metabolic explorer (metex.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Governance Reshuffle: CEO Successions, Activist Settlements and Corporate Separations
Across sectors, boards are replacing or rotating leadership (Bausch + Lomb's abrupt CEO exit, Keyser's move to advisor, Deputy CEO promotions, Brown-Forman and BellRing successions). At the same time, activist pressure is being settled through cooperation agreements and board seats (Stride/Fivespan, Al Shams) and through structural separations (National Fuel's IUG spin-out, NGEx). The common thread is boards using governance levers such as new committees, advisory seats and planned succession to reset capital allocation and strategy. Public messaging stresses continuity and partnership, but the number of interim appointments and activist-driven changes points to underlying pressure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,384 source documents archived
Query this data → isubstrate.com